The identification of the prognostic significance of the CD8+CD103+ TRM cells not only enhance our understanding of TIL heterogeneity but also holds transformative potential for improving the efficacy of melanoma immunotherapy and adoptive cell therapies. The gene discussed is CD8A; the disease is melanoma.